Novartis (NVS) Misses Q4 EPS by 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St set for higher open as investors weigh Mideast negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Novartis (NVS) slides as Q4 EPS, revenue miss estimates
January 31, 2024 7:30 AM ESTNovartis (NYSE: NVS) stock fell 4% in premarket trading Wednesday after the Swiss pharmaceutical company reported worse-than-expected core earnings for the fourth quarter.
Concretely, Novartis posted Q4 core earnings per share (EPS) of $1.53, missing the consensus projection of $1.66. Revenue came in at $11.42 billion, also below the estimated... More
